India · Delayed Price · Currency is INR Metropolis Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
Q3 saw 26% group revenue growth and 29% organic EBITDA growth year-on-year, with strong performance across B2C and B2B segments and expanding margins. Strategic focus on genomics, digital, and network expansion continues, while a 3:1 bonus share issue was announced.
-
Group revenue grew 23% year-over-year with strong organic margin expansion and double-digit volume growth. Integration of recent acquisitions is progressing, and guidance for margin and top-line growth is maintained for FY2026.
-
Q1 FY2026 saw 23% group revenue growth and 13.2% organic growth, with margin expansion and strong performance in specialty and preventive diagnostics. Integration of recent acquisitions is on track, and further growth is expected in Tier 2/3 markets and B2C share.
Fiscal Year 2025
-
FY25 saw 12% revenue growth, strong B2C momentum, and three strategic acquisitions to boost North India presence. FY26 guidance is for 25-26% total revenue growth, 100 bps organic margin expansion, and continued focus on operational efficiency and digital transformation.
-
Q3 FY25 saw 11% revenue growth, with B2C now 55% of revenue and strong gains in wellness and specialty testing. The Core Diagnostics acquisition is set to close soon, expected to be EPS accretive from year one, with margin normalization in 2-3 years. Margin guidance remains at 25%+ for Q4 and beyond.
-
Q2 FY25 saw 13.4% revenue growth, 22% EBITDA growth, and 31% PAT growth, driven by strong B2C and specialty segments, network expansion in tier 3/4 cities, and digital initiatives. Margins are expected to improve as new labs mature, with guidance maintained at 13%-15% revenue growth.
-
Q1 FY25 saw 13.1% revenue growth, margin expansion, and strong B2C and TruHealth performance. Expansion into Tier 3/4 markets and digital initiatives continue, with FY25 revenue growth guided at 13%-15% and EBITDA margin at 25%-26%.
Fiscal Year 2024
-
The acquisition of Core Diagnostics strengthens the specialized oncology testing portfolio, expands reach in North and East India, and is expected to be EPS accretive from FY26. Integration will focus on operational synergies, cross-selling, and cost efficiencies, positioning the combined entity as a leader in cancer diagnostics.